Table 1 Conclusion
From: Abstracts from the 8th Drug Hypersensitivity Meeting (DHM)
References | HS type/number of patients | Dose for challenge |
|---|---|---|
Trcka J et al. AJR Am J Roentgenol 2008 | Immediate HS/2 | 49.05Â mL |
Salas M, et al. Allergy 2013 | Immediate HS/8 (and 14 challenges with various ICM) | 100Â mL |
Prieto-Garcia et al. J Investig Allergol Clin Immunol 2013 | Immediate HS/5 | 120 mL (n = 3), 24 mL (n = 1), 14 mL (n = 1) |
Sese et al. Clin Exp Allergy 2016 | Immediate HS/37 | 10Â mL |
Vernassiere C et al. Contact Dermatitis 2004 | Delayed HS/5 | 10Â mL |
Seitz CS, et al. Eur J Radiol 2009 | Delayed HS/4 | 53.5Â mL |
Torres MJ, et al. Allergy 2012 | Delayed HS/44 | 100Â mL (cumulative dose) |
Lerondeau B, et al. J Allergy Clin Immunol 2016 | Delayed and immediate HS/340 | 10Â mL (10th of the full dose) |